Abstract
Uterine inflammatory myofibroblastic tumor (IMT) is a rare type of mesenchymal tumor that usually follows an indolent course, although it can behave aggressively in a minority of cases. The most common clinical presentations are abnormal uterine bleeding and pelvic discomfort. Radiographic features are non-specific, typically showing a myometrial mass with heterogeneous enhancement and, occasionally, infiltrative margins. Histologically, IMTs are composed of spindle myofibroblasts in a myxoid to compact stroma with an inflammatory infiltrate, and they often exhibit anaplastic lymphoma kinase (ALK) gene fusions and ALK positivity. The main treatment approach is surgical excision, with ALK inhibitors as a therapeutic option in selected cases.